Trial intelligence / Profile preview

Zanubrutinib vs bendamustine + rituximab in untreated CLL/SLL ineligible for FCR

CTR20190416Phase 3Completed

Sponsor

BeiGene

Start

Mar 2019

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1